IRB Problems Will Increase Congressional Pressure On Industry Trial Designs
Executive Summary
Congress may be looking to limit the flexibility that firms have in conducting clinical trials following a study that revealed operational shortcomings in the conduct and registration of Institutional Review Boards
You may also be interested in...
Single IRB Policy For Multi-Site Trials May Soon Get White House OK; NCI Hopeful
The White House appears close to finalizing a policy that would allow multi-site clinical trials to use only one institutional review board, which National Cancer Institute and other officials think could speed up and improve the process.
Single IRB Policy For Multi-Site Trials May Soon Get White House OK; NCI Hopeful
The White House appears close to finalizing a policy that would allow multi-site clinical trials to use only one institutional review board, which National Cancer Institute and other officials think could speed up and improve the process.
Who's Watching The Watchmen This Time? The Mystery Of The New IRB Sting
Institutional review boards appear to be facing vigilante regulation as FDA warns that someone is submitting fictitious studies for review.